North Macedonia Medical Cannabis: The Patient Access Gap

Photo by Juan Pérez Gallego via Pexels.

The headline premise is that import quotas are leaving North Macedonia's medical cannabis patients with empty pharmacy shelves. I could not confirm it. No source I found describes an import-quota regime, and none documents shortages in the way the framing implies. So this article tests the claim instead of assuming it.

The backdrop is odd enough on its own. By 2021 the country had more than 60 licensed cannabis producers, according to Balkan Insight. Yet an overview from Prohibition Partners in 2025 says domestic patient access remains minimal.

What follows is a map in three layers: what is documented, what is only alleged, and what nobody has yet verified. Laws and enforcement in this area are moving quickly, so treat everything here as a starting point and check current details with official sources.

Testing the Import Quota Premise

Photo by https://kaboompics.com/ via Pexels.

Start with what the research did not find. No source describes an import-quota regime for medical cannabis in North Macedonia. The country is described mainly as a producer and exporter, which is close to the opposite of a quota-constrained importer.

I also found no INCB quota figures for cannabis or cannabinoids in the country. No Ministry of Health or MALMED statement on shortages turned up either. Without those, a claim that quotas cause shortages has nothing to stand on.

It helps to separate two problems that often get blurred. A shortage means something that was stocked has run out. An access gap means the product was never realistically available, because pharmacies are not equipped or patients cannot afford it. A cannabis medicine can be missing from a pharmacy with no quota involved at all.

Quotas may still matter somewhere in the chain. But that is a hypothesis, not a finding. Anyone writing or reading about this should check current figures with MALMED, the Ministry of Health and INCB reports, since rules change.

How the 2016 Framework Works

Photo by CRYSTALWEED cannabis via Unsplash.

Medical cannabis became legal on February 9, 2016, when the Parliament Health Committee approved it. That was early for the Balkans, and the government sold it as an investment opportunity.

Patient access came a few months later. Since June 2016, patients can buy oil containing 0.2 percent cannabinoids or less without a prescription. More concentrated forms require one.

The government investment agency says the country adopted the Canadian open model for cannabis-based products rather than a state monopoly. In practice that means private companies, not a state body, do the growing and processing, under licence.

Oversight is split. The Ministry of Health, the Agency for Medicines and Medical Devices (MALMED) and the Ministry of Interior all have a hand, and cultivation and processing need separate permits. Operators must also meet GACP and GMP standards, the agricultural and manufacturing benchmarks borrowed from the pharmaceutical world.

Three agencies and two permit tracks make for a demanding system on paper. Whether it works as designed is what the 2026 events call into question.

What Patients Actually Face

Prohibition Partners' 2025 overview is blunt: domestic patient access remains minimal. It adds that very few pharmacies are equipped to dispense cannabis-based medicines. That is an access problem, not a quota problem.

The same overview says there is no public reimbursement. Patients pay the full cost of treatment themselves. The page is roughly a year old, so it may be outdated, but nothing I found contradicts it.

The investment agency offers broader context. It says the country imports over 50 percent of its medical products. The figure is undated and not specific to cannabis, so it should not be read as evidence about cannabis supply. It does show a pharmaceutical market that leans heavily on outside supply.

One gap matters here. I found no testimony from patient groups or pharmacists describing shortages. The lived experience is therefore only partly documented, and anyone claiming to know what patients face day to day should show their source.

An Export-First Industry

Balkan Insight reports that by 2021 the country boasted more than 60 licensed cannabis producers. Cultivation was legalised in 2016 and promoted heavily by the government of the time. That is a lot of licences for a small market.

The export rules shape what those companies make. Exports are allowed for extracts and oil-based products. Dried flower remains prohibited for international trade.

Buyers are also restricted. Exports go only to countries with legal medical cannabis frameworks and reciprocal import permissions. Each shipment therefore depends on a foreign regulator saying yes.

My reading is that this structure points the industry at foreign buyers. A licensed producer chasing export contracts in Europe has little reason to build a retail pipeline for a few patients paying out of pocket in Skopje. That does not prove deliberate neglect, but it fits the thin domestic supply better than a quota story does.

The 2026 Seizures and the Diversion Question

Cannareporter, on February 13, 2026, called the situation the most serious crisis for the sector since regulation. It pointed to a record seizure of five tons of illicit cannabis in Serbia at the end of January 2026.

Serbia's Prosecutor's Office for Organized Crime said the group acquired the cannabis between January 1 and 29, 2026, in North Macedonia and moved it to Belgrade.

The same report cites confiscation of more than 40 tons of medicinal cannabis products inside North Macedonia. Authorities reportedly found discrepancies between licensed production records and the quantities found. The exact source of the 40-ton figure is unclear, so treat it cautiously.

Investigators suspect diversion to the black market. These are allegations. Balkan Insight, in April 2026, names companies and individuals in connection with new seizures, but people named in news accounts have not been convicted.

A former prime minister, Zoran Zaev, denied links to the cases and called the accusation a blatant lie. Balkan Insight says the new seizures cast further doubt on the state's ability to keep the industry in check.

What Still Needs Verifying

Several things would settle the question. Here is the list I would chase:

• Any 2026 licence suspensions, revocations or tightened rules after the seizures. These, rather than quotas, may be the real driver of supply problems.
• MALMED or Ministry of Health data on which cannabis-based medicines are registered and stocked in pharmacies.
• INCB estimates or quota figures for cannabis and cannabinoids for North Macedonia.
• Statements from patient groups or pharmacists on shortages.

Until those arrive, the shortage story rests on inference. The documented parts are the 2016 framework, the export orientation and the minimal pharmacy access. The alleged parts are diversion and record mismatches.

Laws and enforcement shift quickly, especially after a scandal. Confirm current specifics with MALMED, the Ministry of Health and INCB publications before relying on anything here.

The better question is not why quotas cause shortages. It is why a country built to export cannabis medicine has so little of it reaching its own patients. The evidence points to pharmacy capacity, cost and an export-first industry, not to import limits.

The 2026 seizures make oversight the story to watch. If regulators tighten licences, legitimate supply could become cleaner, or it could be squeezed further. Domestic patients, who already pay in full and find few pharmacies able to help, are the ones who would feel either outcome first.

Browse our seed collection.